About Us

Revive is a clinical-stage company focused on commercializing treatments for Gout and orphan drug indications such as, Cystinuria, Wilson disease and Rett syndrome.  Revive’s business model employs a lower risk drug development and commercial strategy by focusing on finding new uses of old drugs through drug repurposing with the objective of finding an appropriate partner or partners to bring the new use drug to the marketplace.  

Read more

news

News

May 20, 2015

Revive Therapeutics Announces Results for the Three and Nine Months Ended March 31, 2015

Read more
May 04, 2015

Revive Therapeutics to Present at Marcum MicroCap Conference

Read more
April 27, 2015

Revive Therapeutics Announces Positive Study Results from its Research Collaboration with Rettsyndrome.org

Read more
April 15, 2015

Bruce N. Cronstein, MD, Joins Revive Therapeutics as Medical Advisor

Read more
March 05, 2015

Revive Therapeutics Enters Into Advisory Agreement with Spinnaker Capital Markets Inc.

Read more
Newsletter
Corporate presentation

 

Presentation

August 11, 2015